These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
737 related articles for article (PubMed ID: 9553667)
41. The response of breast cancer cells to steroid and peptide growth factors. Godden J; Leake R; Kerr DJ Anticancer Res; 1992; 12(5):1683-8. PubMed ID: 1444236 [TBL] [Abstract][Full Text] [Related]
42. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841 [TBL] [Abstract][Full Text] [Related]
43. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines. Néri C; Berthois Y; Schatz B; Drieu K; Martin PM Breast Cancer Res Treat; 1990 Feb; 15(2):85-93. PubMed ID: 2138918 [TBL] [Abstract][Full Text] [Related]
44. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544 [TBL] [Abstract][Full Text] [Related]
45. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. van Agthoven T; van Agthoven TL; Dekker A; Foekens JA; Dorssers LC Mol Endocrinol; 1994 Nov; 8(11):1474-83. PubMed ID: 7533260 [TBL] [Abstract][Full Text] [Related]
46. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Guvakova MA; Surmacz E Cancer Res; 1997 Jul; 57(13):2606-10. PubMed ID: 9205064 [TBL] [Abstract][Full Text] [Related]
47. Insulin-like growth factors control the regulation of oestrogen and progesterone receptor expression by oestrogens. Clayton SJ; May FE; Westley BR Mol Cell Endocrinol; 1997 Apr; 128(1-2):57-68. PubMed ID: 9140076 [TBL] [Abstract][Full Text] [Related]
48. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Kim J; Lee J; Kim C; Choi J; Kim A Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908 [TBL] [Abstract][Full Text] [Related]
49. [Tamoxifen in the treatment of breast cancer]. Charlier C; Colin C; Merville MP; Gielen J; Lambotte R; Plomteux G; Castronovo V J Gynecol Obstet Biol Reprod (Paris); 1994; 23(7):751-6. PubMed ID: 7822705 [TBL] [Abstract][Full Text] [Related]
50. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Knowlden JM; Hutcheson IR; Jones HE; Madden T; Gee JM; Harper ME; Barrow D; Wakeling AE; Nicholson RI Endocrinology; 2003 Mar; 144(3):1032-44. PubMed ID: 12586780 [TBL] [Abstract][Full Text] [Related]
51. Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Berthois Y; Dong XF; Martin PM Biochem Biophys Res Commun; 1989 Feb; 159(1):126-31. PubMed ID: 2784313 [TBL] [Abstract][Full Text] [Related]
52. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Daly RJ; Darbre PD Cancer Res; 1990 Sep; 50(18):5868-75. PubMed ID: 2393857 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of breast cancer growth by suramin. Vignon F; Prebois C; Rochefort H J Natl Cancer Inst; 1992 Jan; 84(1):38-42. PubMed ID: 1738172 [TBL] [Abstract][Full Text] [Related]
54. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Thrane S; Lykkesfeldt AE; Larsen MS; Sorensen BS; Yde CW Breast Cancer Res Treat; 2013 May; 139(1):71-80. PubMed ID: 23609470 [TBL] [Abstract][Full Text] [Related]
55. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. DeFriend DJ; Anderson E; Bell J; Wilks DP; West CM; Mansel RE; Howell A Br J Cancer; 1994 Aug; 70(2):204-11. PubMed ID: 8054267 [TBL] [Abstract][Full Text] [Related]
56. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Noguchi S; Motomura K; Inaji H; Imaoka S; Koyama H Cancer; 1993 Jul; 72(1):131-6. PubMed ID: 8508397 [TBL] [Abstract][Full Text] [Related]
57. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. Wakeling AE; Newboult E; Peters SW J Mol Endocrinol; 1989 May; 2(3):225-34. PubMed ID: 2665780 [TBL] [Abstract][Full Text] [Related]
58. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Favoni RE; de Cupis A; Bruno S; Yee D; Ferrera A; Pirani P; Costa A; Decensi A Br J Cancer; 1998 Jun; 77(12):2138-47. PubMed ID: 9649125 [TBL] [Abstract][Full Text] [Related]
59. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Larsen SS; Heiberg I; Lykkesfeldt AE Br J Cancer; 2001 Mar; 84(5):686-90. PubMed ID: 11237391 [TBL] [Abstract][Full Text] [Related]
60. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer. Chong K; Subramanian A; Sharma A; Mokbel K Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]